What we have achieved

2000Volunteers recruited
250Completed trials since 1996
70Investigator Initiated Trials completed
180Industry Sponsored Trials completed

Ongoing clinical trials in IMU

Phase 4 Adverse Drug Reaction study on serious skin rash

Pharmacogenetics of Adverse Drug Reactions – Serious Skin Rash

Phase 3 Allergy study to investigate the effect of a partially hydrolysed infant formula with added synbiotics (Maestro)

A randomised, double-blind, controlled, parallel-group, multi-country study to investigate the effect of a partially hydrolysed infant formula with added synbiotics on the development of allergic manifestations in infants at high risk of developing allergy. (Maestro)

Phase 3 haematology study to evaluate the safety and efficacy of ALXN1210 compared to eculizumab

Phase 3 haematology study to evaluate the safety and efficacy of ALXN1210 compared to eculizumabStudy Details This is a Phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the safety and efficacy of ALXN1210 versus eculizumab administered by intravenous (IV) infusion to adult patients with PNH who are naïve to complement inhibitor treatment. Protocol Number …

Phase 3 haematology study to evaluate the safety and efficacy of ALXN1210 compared to eculizumabRead More »

Volunteers

Be a hero to others today!

Be part of a journey to discover new therapies to improve the future of healthcare.

Partners

Interested to work together with us?

Collaborate with IMU to discover better treatments for a better tomorrow.